Prevention of Lateral Incisional Hernia After Stomal Closure Using P4HB Retro-muscular Mesh

Sponsor
Buccheri La Ferla Hospital, Palermo (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04538768
Collaborator
(none)
150
1
2
30
5

Study Details

Study Description

Brief Summary

The aim of the study is to determine whether the use of the P4HB retro muscular mesh can prevent the lateral incisional hernia after stomal closure.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Mesh augmentation
  • Procedure: Direct suture
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Prevention of Lateral Incisional Hernia After Stomal Closure Using P4HB Retro-muscular Mesh
Anticipated Study Start Date :
Oct 1, 2020
Anticipated Primary Completion Date :
Oct 1, 2021
Anticipated Study Completion Date :
Apr 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Mesh Augmentated

Procedure: Mesh augmentation
P4HB retromuscular mesh placement for prevention of lateral incisional hernia after stomal closure

Other: Direct Suture

Procedure: Direct suture
direct fascia suture

Outcome Measures

Primary Outcome Measures

  1. rate of postoperative lateral incisional hernia after P4HB mesh placement vs direct fascia suture. [1 week to 18 months after surgery]

    the outcome 1 will be assessed through clinical examination during follow up time. when the suspicion of incisional hernia will be hypothesized the patients will be conducted to perform US of the abdomen and CT scan of the abdomen if strictly required to confirm the suspicion.

Secondary Outcome Measures

  1. surgical operation time in P4HB mesh placement group vs direct fascia suture group. [intraoperative]

    outcome 2 will be assessed through the measurement of the length of surgical operation. The length of the surgical operation will be measured in minutes from the incision of the skin to the suture of the skin. data will be compared with those of the control arm (direct fascia suture) to understand the feasibility of the technique proposed.

  2. length of hospital stay in P4HB mesh placement group vs direct fascia suture group. [From the starting date of the study until the date of its completion, assessed up to 18 months"]

    outcome 3 will be assessed through the measurement of the length of the hospital stay. The length of hospital stay will be measured in days from admission to dimission of the patient. Data will be compared with those of the control arm (direct fascia suture).

  3. rate of surgical site infection in P4HB mesh placement group vs direct fascia suture group. [1 week after surgery; 1 month after surgery; 3 months after surgery; 6 months after surgery; 12 months after surgery; 18 months after surgery]

    outcome 4 will be assessed through clinical examination during follow up time evaluating the rate of postoperative complication such as surgical site infection.

  4. rate of seroma formation in P4HB mesh placement group vs direct fascia suture group. [1 week after surgery; 1 month after surgery; 3 months after surgery; 6 months after surgery; 12 months after surgery; 18 months after surgery]

    outcome 5 will be assessed through clinical examination during follow up time evaluating the rate of postoperative complications such as seroma.

  5. rate of hematoma formation in P4HB mesh placement group vs direct fascia suture group. [1 week after surgery; 1 month after surgery; 3 months after surgery; 6 months after surgery; 12 months after surgery; 18 months after surgery]

    outcome 6 will be assessed through clinical examination during follow up time evaluating the rate of postoperative complications such as hematoma.

  6. assessment of quality of life (QoL) through QoL scale in P4HB mesh placement group vs direct fascia suture group. [18 months after surgery.]

    outcome 7 will be assessed through assessment of the postoperative QoL. The SF-36 questionnaire will be administered post-operatively. The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. The SF-36, as described in the name, is a 36-item patient-reported questionnaire that covers eight health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical health problems (4 items), role limitations due to personal or emotional problems (4 items), emotional well-being (5 items), social functioning (2 items), energy/fatigue (4 items), and general health perceptions (5 items). Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state.

  7. cost effectiveness analysis of the P4HB mesh augmentation technique vs direct fascia suture group. [through study completion, an average of 1 year .]

    the outcome 8 will be assessed through the collection of data about the total costs for the surgical operation and the hospitalization considering materials and mesh used. The analysis will be used to compare the costs of the technique proposed with those of the incisional hernia management in order to conduct a cost effectiveness analysis.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients > 18 y.o.

  • stomal closure

  • elective surgery

Exclusion Criteria:
  • patients < 18 y.o.

  • emergency surgery

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ospedale Buccheri La Ferla Palermo Palermo Italy 90100

Sponsors and Collaborators

  • Buccheri La Ferla Hospital, Palermo

Investigators

  • Study Director: Leo Licari, MD, Ospedale Buccheri La Ferla Palermo; University of Palermo - Department of Surgical, Oncological and Oral Sciences
  • Study Chair: Cosimo Callari, MD, Ospedale Buccheri La Ferla Palermo

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Leo Licari, Principal Investigator, Buccheri La Ferla Hospital, Palermo
ClinicalTrials.gov Identifier:
NCT04538768
Other Study ID Numbers:
  • 20082020
First Posted:
Sep 4, 2020
Last Update Posted:
Sep 4, 2020
Last Verified:
Aug 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Leo Licari, Principal Investigator, Buccheri La Ferla Hospital, Palermo
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 4, 2020